傑龍 GERN 深 滬
等待開盤 11-26 09:30:00 美东时间
1.16
0.000
0.00%
華盛通- 最 高1.17
- 今 開1.16
- 成交量 624.03万股
- 最 低 1.13
- 昨 收 1.16
- 總市值 7.40亿
- 52周最高 4.085
- 市盈率 靜 --
- 換手率 0.98%
- 52周最低 1.04
- 委 比 -51.25%
- 總股本 6.38亿
- 歷史最高 7.79
- 量 比 0.79
- 振 幅 3.45%
- 歷史最低 0.75
- 每 手 1
- 風險率 0.88%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
11-06 09:55
Needham Maintains Buy on Geron, Lowers Price Target to $4
Needham analyst Gil Blum maintains Geron (NASDAQ:GERN) with a Buy and lowers the price target from $5 to $4.
11-06 01:23
Geron Expects 2025 Operating Expenses Will Be Between $250M And $260M vs. Approximately $270M-$285M Prior
2025 Financial GuidanceFor fiscal year 2025, the Company expects total operating expenses will be between $250 million and $260 million, compared to previously announced guidance of approximately $270 million to $285
11-05 20:12
Earnings Scheduled For November 5, 2025
Companies Reporting Before The Bell • Avient (NYSE:AVNT) is estimated to report...
11-05 19:12
新浪财经ESG：杰龙 MSCI（明晟）ESG评级调降至BBB
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。点击查看【 ESG评级中...
11-05 07:00
Geron To Present New RYTELO Data On LR-MDS And Myelofibrosis At ASH 2025
New analysis from the Phase 3 IMerge clinical trial, accepted as an oral presentation, explores relationship between treatment-emergent cytopenias and clinical response in LR-MDSAdditional poster presentations include
11-03 22:11
优秀！永康籍运动员入围2026年米兰冬奥会主力阵容
（来源：永康人） 近日，记者从永康三中体育教师吕杨处获悉，其曾培养的学生叶杰龙，已入围2026年冬奥会男子四人雪车项目参赛名单。 叶杰龙...
10-30 09:03
Geron announces executive leadership changes, new appointments
Geron Corporation (NASDAQ:GERN) on Monday said it will make several executive leadership changes this month as part of a restructuring to align with its commercial priorities. Chief Operating Officer ...
10-14 04:44
Geron's COO Andrew Grethlein To Depart On October 15, 2025
FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced several
10-14 04:42
Geron Corporation Announces Executive Leadership Transitions and Appointments
Geron Corporation has appointed four new executives to strengthen its leadership team, including Ahmed ElNawawi as Executive Vice President and Chief Commercial Officer, effective October 20, 2025. ElNawawi brings extensive experience in commercial leadership and oncology drug launches. Additionally, Shanthakumar Tyavanagimatt, Dawn Schottlandt, and Bryan Ridgell have joined as Senior Vice Presidents in technical operations, investor relations, a...
10-13 20:34
